Reilly Kevin C 4
4 · KESTRA MEDICAL TECHNOLOGIES, LTD. · Filed Mar 12, 2026
Research Summary
AI-generated summary of this filing
Kestra Medical (KMTS) Director Kevin Reilly Receives 8,300 RSUs
What Happened
- Kevin C. Reilly, a director of Kestra Medical Technologies, Ltd. (KMTS), was granted 8,300 restricted stock units (RSUs) on March 11, 2026. The filing reports this as an Award/Grant (transaction code A). No purchase price or total value is shown in the filing (price listed as N/A).
Key Details
- Transaction date: March 11, 2026 (Form 4 filed March 12, 2026 — within the typical two-business-day reporting window).
- Grant: 8,300 RSUs; acquisition price: N/A (award).
- Shares owned after transaction: not specified in the filing.
- Footnote: Each RSU converts to one common share; the RSUs vest on September 4, 2026, subject to the reporting person’s continued service through that date.
Context
- RSUs are a form of equity compensation that convert to actual shares only upon vesting; this grant does not represent an immediate open-market purchase or sale. Such awards are common for executive and board compensation and do not by themselves indicate near-term buying or selling intentions.
Insider Transaction Report
Form 4
Reilly Kevin C
Director
Transactions
- Award
Common Shares
[F1]2026-03-11+8,300→ 8,300 total
Footnotes (1)
- [F1]The reported securities represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest on September 4, 2026, subject to the Reporting Person's continued service through such date.
Signature
/s/ Traci S. Umberger as attorney-in-fact for Kevin C. Reilly|2026-03-12